Endotyping Pediatric Chronic Rhinosinusitis using Multiplexed Imaging and Mass Cytometry
Ivan Lee, MD, PhD
BACKGROUND: Current medical therapies for chronic rhinosinusitis (CRS) such as antibiotics, steroids, and nasal sprays are often limited, and non-curative in the majority of patients. Patients who are refractory to medical management may undergo functional endoscopic sinus surgery but about 25% of patients fail to have clinical improvements post-surgery.
GAP: There is a need for identifying reliable biomarkers that provide more accurate and predictive information regarding endotype, treatment response, and recurrence in order to improve therapy for CRS.
HYPOTHESIS: We hypothesize that a ‘signature’ of biomarkers in quantitative or spatial combination will newly define CRS endotype or disease prognosis.
METHODS: The proposed study will be a cohort study and will involve the recruitment of pediatric patients with CRS with and without nasal polyps, patients with CRS and cystic fibrosis, and healthy controls.
IMPACT: Identification of these CRS biomarkers will significantly advance our understanding of the cellular and molecular contributors of CRS to a resolution previously not appreciated, and may lead to novel, personalized therapies for newly-categorized subsets of this difficult-to-treat disease entity.